US EditionEHA 2025: J&J’s dual-targeting bispecifics could redefine SOC for r/r MM
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
EHA 2025: J&J’s dual-targeting bispecifics could redefine SOC for r/r MM
At EHA 2025, the preliminary results from the global, multi-centre open-label non-randomised Phase II RedirecTT-1 clinical trial were presented.The post EHA 2025: J&J’s dual-targeting bispecifics could redefine SOC for r/r MM appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
